IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

BAYER INTELLECTUAL PROPERTY)
GMBH, BAYER AG, and JANSSEN)
PHARMACEUTICALS, INC.,)
) C.A. No. 17-462-RGA
Plaintiffs,) (consolidated)
)
V.) HIGHLY CONFIDENTIAL -
) FILED UNDER SEAL
MYLAN PHARMACEUTICALS INC.,)
)
Defendants.)

LETTER TO THE HONORABLE RICHARD G. ANDREWS FROM BINDU A. PALAPURA

OF COUNSEL:

Douglas H. Carsten Elham Firouzi Steiner WILSON SONSINI GOODRICH & ROSATI P.C. 12235 El Camino Real, Suite 200 San Diego, CA 92130 Tel: (858) 350-2300

David M. Hanna Kristina M. Hanson WILSON SONSINI GOODRICH & ROSATI P.C. One Market – Spear Tower, Suite 3300 San Francisco, CA 94105 Tel: (415) 947-2000

Dated: September 21, 2018 5936096 / 44258

DOCKET

David E. Moore (#3983) Bindu A. Palapura (#5370) Stephanie E. O'Byrne (#4446) POTTER ANDERSON & CORROON LLP Hercules Plaza, 6th Floor 1313 N. Market Street Wilmington, DE 19801 Tel: (302) 984-6000 dmoore@potteranderson.com bpalapura@potteranderson.com obyrne@potteranderson.com

Attorneys for Defendant Mylan Pharmaceuticals Inc.

MyLAN - EXHIBIT 1067 Mylan Pharmaceuticals Inc. y Rover Intellectual Property CmbH

Find authenticated court documents without watermarks at docketalarm.com.



1313 North Market Street P.O. Box 951 Wilmington, DE 19801- 0951 302 984 6000 www.potteranderson.com

Bindu A. Palapura

Partner Attorney at Law bpalapura@potteranderson.com 302 984-6092 Direct Phone 302 658-1192 Firm Fax

September 21, 2018

VIA ELECTRONIC FILING

The Honorable Richard G. Andrews United States District Court for the District of Delaware 844 North King Street Wilmington, DE 19801

HIGHLY CONFIDENTIAL – FILED UNDER SEAL

Re: *Bayer Intellectual Property GmbH v. Taro Pharmaceutical Industries, Ltd.* C.A. No. 17-462 (RGA)

Dear Judge Andrews:

Our firm, along with the firm of Wilson Sonsini Goodrich & Rosati, represents defendant Mylan Pharmaceuticals Inc. ("Mylan") in the above matter. We write in response to Plaintiffs Bayer Intellectual Property GmbH, Bayer AG, and Janssen Pharmaceuticals Inc.'s ("collectively, Plaintiffs") September 18, 2018 letter to the Court. Plaintiffs' request for additional briefing on a claim term that has already been construed by this Court has no support in the law and is a waste of the parties' and the Court's time and resources. In short, Plaintiffs' request amounts to an improper reconsideration motion and should be denied.

Pursuant to the Court's Scheduling Order (D.I. 20), the parties submitted a Joint Claim Construction Brief on June 22, 2018. Plaintiffs set forth detailed arguments in support of their proposed construction

Plaintiffs

argued that this construction was the express definition of "rapid-release tablet" contained in the specification. Indeed, Plaintiffs argued *no less than 25 separate times* in their briefs that their proposed construction was the express definition of "rapid-release tablet." Plaintiffs had a full and fair opportunity to present their construction.


On July 3, 2018, this Court issued its *Markman* Order. The Court considered the parties' arguments, reviewed the intrinsic evidence, and adopted Plaintiffs' own lexicography, construing the term "rapid-release tablet" in U.S. Patent No. 9,539,218 ("the '218 patent") to mean "a tablet which, according to the USP release method using apparatus 2 (paddle), has a Q value (30 minutes) of 75%." *See* D.I. 91 at 1.

Plaintiffs

The Honorable Richard G. Andrews September 21, 2018 Page 2

unequivocally stated that the "express definition governs the claim construction inquiry, and there is no need for the Court to search further for the meaning of the phrase." D.I. 82 at 4.

Moreover, despite Plaintiffs' assertions to the contrary, Mylan's claim construction position regarding "rapid-release tablet" is irrelevant as it was rejected by Plaintiffs and the Court. Notwithstanding, Mylan's claim construction position is



Plaintiffs "should be bound by the litigation decisions they ma[d]e." *Reckitt Benckiser Pharms. Inc., et al. v. Watson Labs., Inc., et al.*, C.A. No. 13-1674-RGA (consolidated), D.I. 479 at 5 (D. Del., August 31, 2017).

Re-opening claim construction at this time would not only be improper and highly prejudicial to Mylan but also a waste of the Court's and the parties' resources. Plaintiffs' request amounts to a belated request for reconsideration. However, such requests are meant to "correct manifest errors of law or fact or to present newly discovered evidence." *Celebrate Int'l LLC v. Leapfrog Enterprises Inc., et al,* C.A. No. 14-261-RGA (D. Del. June 16, 2016) (citing *Max's Seafood Café ex re. Lou-Ann, Inc. v. Quinteros,* 176 F. 3d 669, 677 (3d. Cir. 1999)). Neither of these considerations is present here.

Plaintiffs' request for additional briefing on a claim term that has already been fully briefed and construed by the Court is unsupported and should be denied.

Respectfully, /s/ Bindu A. Palapura Bindu A. Palapura

BAP/msb/5936096/44258

DOCKE

cc: Clerk of the Court (via hand delivery) Counsel of Record (via electronic mail)

Find authenticated court documents without watermarks at <u>docketalarm.com</u>.